For breast carcinoma patients, approximately 20% have copy number amplification of receptor tyrosine-protein kinase erbB-2 (ERBB2) gene, resulting in highly expressed ErbB2 protein (12), which is associated with increased tumor aggressiveness, relapse, and mortality (13). This evidence concerns the gene ERBB2 and neoplasm.